120 related articles for article (PubMed ID: 10869655)
1. Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis.
Khan A; Caride VJ
Urology; 2000 Jul; 56(1):154. PubMed ID: 10869655
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
4. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
5. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
6. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.
Wong WW; Schild SE; Vora SA; Ezzell GA; Nguyen BD; Ram PC; Roarke MC
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e423-9. PubMed ID: 21477947
[TBL] [Abstract][Full Text] [Related]
7. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer.
Anderson RS; Eifert B; Tartt S; King P
Urology; 2000 Oct; 56(4):669. PubMed ID: 11018634
[TBL] [Abstract][Full Text] [Related]
9. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
[TBL] [Abstract][Full Text] [Related]
10. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
Sodee DB; Conant R; Chalfant M; Miron S; Klein E; Bahnson R; Spirnak JP; Carlin B; Bellon EM; Rogers B
Clin Nucl Med; 1996 Oct; 21(10):759-67. PubMed ID: 8896922
[TBL] [Abstract][Full Text] [Related]
11. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
Petronis JD; Regan F; Lin K
Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
[TBL] [Abstract][Full Text] [Related]
12. Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
Lamb HM; Faulds D
Drugs Aging; 1998 Apr; 12(4):293-304. PubMed ID: 9571393
[TBL] [Abstract][Full Text] [Related]
13. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
ProaƱo JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
14. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
[TBL] [Abstract][Full Text] [Related]
15. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy.
Welsh JS; Yanez MH; Chin BB; Howard SP
Clin Nucl Med; 1999 Dec; 24(12):983. PubMed ID: 10595485
[No Abstract] [Full Text] [Related]
16. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology.
Wong TZ; Turkington TG; Polascik TJ; Coleman RE
AJR Am J Roentgenol; 2005 Feb; 184(2):676-80. PubMed ID: 15671397
[No Abstract] [Full Text] [Related]
17. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
[TBL] [Abstract][Full Text] [Related]
19. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
20. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
Tolmachev V; Malmberg J; Estrada S; Eriksson O; Orlova A
Int J Oncol; 2014 Jun; 44(6):1998-2008. PubMed ID: 24718894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]